October 13, 2021 | Highland, MD – The Jayne Koskinas Ted Giovanis Foundation for Health and Policy has extended prior JKTGF funded research to Heiko Enderling, Ph.D., a faculty member of Moffitt Cancer Center, to support his work personalizing radiation therapy to better fight breast cancer.
It is now widely recognized that breast cancer therapy should be tailored to individual patients. While patient-specific data has affected the decision for use of chemotherapy, it has yet to impact radiation therapy, the single most used therapeutic treatment in oncology.
This research seeks to decipher the architecture of the tumor-immune ecosystem in biopsy tissues to identify the optimal radiation protocol – on a per-patient basis – to induce robust immunity and eradicate the tumor.
“Radiation therapy is the most used therapy for fighting breast cancer, yet no clinical trials have attempted to individualize it,” said Ted Giovanis, founder and president of the JKTG Foundation.
“Heiko’s research has challenged current practice with exciting results, and the Foundation is pleased to further support his work so future breast cancer patients benefit from individualized treatment and better outcomes.”
We all know vitamin C helps boost immunity with the added bonus of providing anti-inflammatory and antioxidant benefits, but new research gives us another reason to add the vitamin to our diets.
In 2022, JKTG Foundation work focuses on rethinking health care quality, emerging cancer research, and uses for real-world evidence.
The decision to make a charitable contribution to a research or academic institution should be based on a thoughtful process.